<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235741</url>
  </required_header>
  <id_info>
    <org_study_id>DFA104</org_study_id>
    <nct_id>NCT01235741</nct_id>
  </id_info>
  <brief_title>A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controled, Multicenter Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects Following A Low‑Calorie Diet Lead-In</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following screening, eligible subjects will be enrolled into a 6‑week Low Calorie Diet (LCD)
      lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week
      LCD lead-in period will be randomized to 1 of 2 treatment arms (pramlintide+metreleptin or
      placebo) to begin a 16-week treatment period during which the effect on body weight of
      treatment with pramlintide+metreleptin will be compared to placebo. Following the 16 week
      blinded core treatment period, subjects will discontinue study medication for a period of 12
      weeks. Following the 12 week off-drug follow-up period, subjects in both groups will initiate
      a 12 week open-label treatment period with Pramlintide+Metreleptin. During the 12 week
      off-drug and 12 week open label treatment periods, subjects will continue to participate in a
      Lifestyle Intervention (LSI) program.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in invitro
    assay in 2 participants.
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population</measure>
    <time_frame>Day 1 up to Month 6 Follow-Up</time_frame>
    <description>Treatment-Emergent Adverse Events are defined as those with an onset date and time on or after the first dose of randomized study medication and on or before the last dose of randomized study medication. Post-treatment Adverse Events are defined as those with an onset date after the date of last dose (imputed if not available) of randomized study medication. Participants experiencing multiple episodes of a given adverse event are counted once.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat Population</measure>
    <time_frame>Baseline to Month 6 Follow Up</time_frame>
    <description>Participants who received metreleptin were analyzed; no placebo treated participants were analyzed. Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Leptin was measured in nanograms per milliliter (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population</measure>
    <time_frame>Week 1 to Month 6 Follow-Up</time_frame>
    <description>Anti-leptin antibodies measured at Weeks 1 and 2 of drug treatment, early termination visit, and at Months 2, 4, and 6 post treatment follow-up in participants who received metreleptin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Neutralizing Activity to Metreleptin at Early Termination or During Post Treatment Follow-Up - Intent to Treat Population Who Received Metreleptin</measure>
    <time_frame>Baseline to Month 6 Follow-Up</time_frame>
    <description>In vitro assays were conducted to determine if neutralizing activity to metreleptin developed in participants treated with at least one dose of the drug during the study. Baseline is Day 1 of the Randomization Period, prior to administration of metreleptin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hematology and Urinalysis Laboratory Values of Potential Clinical Importance - Intent to Treat Population</measure>
    <time_frame>Screening to 6 Month Follow-Up</time_frame>
    <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Platelets high (H) &gt;500,000/µL; low (L) &lt;75,000/µL. Hematocrit males &lt;36%, females &lt;30%. Hemoglobin males &lt;12 g/dL, females &lt;10 g/dL. White blood cell count (WBC) H &gt;18,000/µL; L &lt;1,500/µL. Urine protein H &gt;= 3+ or &gt;= 500 mg/dL. Urine glucose H &gt;= 3+ or &gt;= 500 mg/dL. Urine ketones &gt;= 3+ or Large.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Chemistry Laboratory Value of Potential Clinical Importance - Intent to Treat Population</measure>
    <time_frame>Screening to Month 6 Follow-Up</time_frame>
    <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Total bilirubin High (H) &gt; 2 mg/dL; Plasma or serum glucose fasting or non-fasting H &gt; 200 mg/dL, low (L) &lt; 60 mg/dL; Albumin L &lt;2.5 g/dL; Creatine kinase H &gt; 3*Upper limit of Normal (ULN); Sodium L &lt;130 milliequivalents per liter (mEq/L), H &gt; 150 mEq/L; potassium L&lt;3.0 mEq/L, H&gt; 5.5 mEq/L; bicarbonate L&lt;18 mEq/L, H&gt;35 mEq/L;calcium L &lt;8mg/dL, H&gt; 11 mg/dL; triglycerides H&gt; 500 mg/dL; Cholesterol L &lt; 100 mg/dL, H &gt; 350 mg/dL; Alkaline phosphatase H &gt; 3*ULN; Gamma-glutamyltransferase H&gt;3*ULN; creatinine males &gt; 1.6 mg/dL, females &gt; 1.4 mg/dL; alanine aminotransferase H &gt; 3*ULN; aspartate aminotransferase H &gt; 3*ULN; urea nitrogen H &gt; 45 mg/dL; uric acid males &gt; 10.0 mg/dL, females &gt; 8.0 mg/dL; Phosphorus L &lt; 1.0 mg/dL H &gt; 6.0 mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to Month 6 Follow-Up in Blood Pressure - Intent to Treat Population</measure>
    <time_frame>Baseline to Month 6 Follow-Up</time_frame>
    <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow-up was up to 6 months post treatment. Blood pressure included systolic and diastolic pressures measured in millimeters of mercury (mmHg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to Month 6 Follow-Up in Heart Rate - Intent to Treat Population</measure>
    <time_frame>Baseline up to Month 6 Follow-Up</time_frame>
    <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Heart rate was measured in beats per minute (beats/min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to 6 Month Follow-Up in Fasting Plasma Glucose - Intent to Treat Population</measure>
    <time_frame>Baseline to 6 Month Follow-Up</time_frame>
    <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Fasting glucose measured in milligrams per deciliter (mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to Month 6 Follow-Up in Insulin - Intent to Treat Population</measure>
    <time_frame>Baseline up to Month 6 Follow-Up</time_frame>
    <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Insulin measured in milliunits per liter (mU/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to Month 6 Follow-Up in Lipids - Intent to Treat Population</measure>
    <time_frame>Baseline up to Month 6 Follow-Up</time_frame>
    <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Lipids measured included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and triglycerides. Lipids were measured in milligrams per deciliter (mg/dL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population</measure>
    <time_frame>Baseline up to Month 6 Follow-Up</time_frame>
    <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramlintide+Metreleptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramlintide+Metreleptin</intervention_name>
    <description>Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is obese with a BMI ≥35 to ≤45 kg/m2.

          -  Has stable body weight (not varying by &gt;5% within 3 months prior to study start).

          -  Meets certain requirements with respect to concomitant medications.

          -  Has not smoked or used nicotine-containing products for at least 12 months prior to
             study start.

        Exclusion Criteria:

          -  Has not been enrolled in a weight loss program within 2 months prior to study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Vice President, Research &amp; Development</last_name>
    <role>Study Director</role>
    <affiliation>Amylin Pharmaceuticals, LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2010</study_first_posted>
  <results_first_submitted>August 12, 2013</results_first_submitted>
  <results_first_submitted_qc>November 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2013</results_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pramlintide</keyword>
  <keyword>Metreleptin</keyword>
  <keyword>Obesity</keyword>
  <keyword>Amylin</keyword>
  <keyword>Takeda</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>5 January 2011 Lead-In Period started. 28 September 2011 last participants final visit procedure. Clinics where participants with body mass index [BMI] greater than, equal to (≥)35 kilogram per meter squared (kg/m^2) and less than, equal to (≤)45 kg/m2) could be enrolled.</recruitment_details>
      <pre_assignment_details>6 week lead-in period:low-calorie diet (LCD); 16 week randomized treatment period: participants who lost &gt;=2% body weight at end of LCD were randomized to an arm. Sponsor terminated study during randomization period due to neutralizing activity to metreleptin observed in Study DFA102, NCT00673387. Safety follow-up 2, 4, 6 months post treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Calorie Diet Only</title>
          <description>6 Week Lead-in Period with low calorie diet (LCD); in the last week of the 6 week LCD, self administered subcutaneous (SC) injections of placebo once a day (QD) was initiated and then followed by randomization to either study drug or placebo in the Randomization period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Self administered subcutaneous (SC) injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) twice a day (BID) for 16 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Pramlintide + Metreleptin</title>
          <description>Self administered SC injection of pramlintide 360 micrograms (µg) + metreleptin 5.0 milligrams (mg) BID for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Non-Randomized Low Calorie Diet Lead-In</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213">6 Week LCD period. Those who lost &gt;=2% of body weight were randomized to treatment.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72">Study terminated by Sponsor. 72 randomized to treatment at time study halted.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor terminated study</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to meet weight loss in Period 1</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Randomized to Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0">Study terminated by Sponsor. Maximum exposure to study drug was 30 days.</participants>
                <participants group_id="P3" count="0">Study terminated by Sponsor. Maximum exposure to study drug was 30 days.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor terminated study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up Post Treatment up to Month 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="36">No treatment; those who had been treated with placebo (36) were followed up 6 Months post treatment.</participants>
                <participants group_id="P3" count="36">No treatment; those who had been treated with drug (36) were followed up 6 months post treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="27">9 participants did not complete the 6 month follow up period</participants>
                <participants group_id="P3" count="29">7 participants did not complete the 6 month follow up period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline for all participants (213) was baseline at enrollment (Day 1 of Lead-in period); baseline for participants who were randomized to treatment before study was terminated was Day 1 of randomization (last measurement before first dose of assigned drug).</population>
      <group_list>
        <group group_id="B1">
          <title>Non-Randomized Lead-in LCD</title>
          <description>6 Week Lead-in with low calorie diet (LCD); in the last week of the 6 week LCD, self administered subcutaneous (SC) injections of placebo once a day (QD) was initiated and then followed by randomization to study drug in the Randomization period.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Self administered subcutaneous (SC ) injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) twice a day (BID) for 16 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Pramlintide + Metreleptin</title>
          <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="213"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at Screening is presented.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.1" spread="11.81"/>
                    <measurement group_id="B2" value="46.2" spread="10.84"/>
                    <measurement group_id="B3" value="46.4" spread="10.45"/>
                    <measurement group_id="B4" value="46.1" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <description>Body weight at enrollment measured in kilograms (kg).</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110.86" spread="13.210"/>
                    <measurement group_id="B2" value="109.10" spread="16.850"/>
                    <measurement group_id="B3" value="108.34" spread="12.032"/>
                    <measurement group_id="B4" value="110.13" spread="13.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (BMI) at enrollment measured in kilograms per meter of height squared (kg/m^2).</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.51" spread="2.875"/>
                    <measurement group_id="B2" value="39.17" spread="3.279"/>
                    <measurement group_id="B3" value="39.09" spread="2.869"/>
                    <measurement group_id="B4" value="39.38" spread="2.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population</title>
        <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication.</description>
        <time_frame>Baseline up to Month 6 Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a measurement. Number analyzed (n) for Week 1 provided above; 6 Month Follow-Up n=27, 29, in placebo and Pramlintide + Metreleptin, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 1 and From Baseline to Month 6 Follow-up in Body Weight - Intent to Treat Population</title>
          <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication.</description>
          <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a measurement. Number analyzed (n) for Week 1 provided above; 6 Month Follow-Up n=27, 29, in placebo and Pramlintide + Metreleptin, respectively.</population>
          <units>percentage of change in weight</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.924"/>
                    <measurement group_id="O2" value="-0.26" spread="0.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="6.575"/>
                    <measurement group_id="O2" value="-1.80" spread="6.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population</title>
        <description>Treatment-Emergent Adverse Events are defined as those with an onset date and time on or after the first dose of randomized study medication and on or before the last dose of randomized study medication. Post-treatment Adverse Events are defined as those with an onset date after the date of last dose (imputed if not available) of randomized study medication. Participants experiencing multiple episodes of a given adverse event are counted once.</description>
        <time_frame>Day 1 up to Month 6 Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>On Treatment Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>On Treatment Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Post Treatment Placebo Arm</title>
            <description>From date after the date of last dose (imputed if not available) of randomized study medication up to 6 Months post treatment.</description>
          </group>
          <group group_id="O4">
            <title>Post Treatment Pramlintide + Metreleptin Arm</title>
            <description>From date after the date of last dose (imputed if not available) of randomized study medication up to 6 Months post treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population</title>
          <description>Treatment-Emergent Adverse Events are defined as those with an onset date and time on or after the first dose of randomized study medication and on or before the last dose of randomized study medication. Post-treatment Adverse Events are defined as those with an onset date after the date of last dose (imputed if not available) of randomized study medication. Participants experiencing multiple episodes of a given adverse event are counted once.</description>
          <population>The intent to treat (ITT) population received at least one dose of randomized study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat Population</title>
        <description>Participants who received metreleptin were analyzed; no placebo treated participants were analyzed. Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Leptin was measured in nanograms per milliliter (ng/mL).</description>
        <time_frame>Baseline to Month 6 Follow Up</time_frame>
        <population>All participants who received a dose of metreleptin and provided a sample were analyzed. Number of participants analyzed for Week 2, and follow up Months 2, 4, 6 were 6, and 33, 29, 29, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 2, and to Follow up Months 2, 4, 6 in Fasting Leptin Concentration - Intent to Treat Population</title>
          <description>Participants who received metreleptin were analyzed; no placebo treated participants were analyzed. Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Leptin was measured in nanograms per milliliter (ng/mL).</description>
          <population>All participants who received a dose of metreleptin and provided a sample were analyzed. Number of participants analyzed for Week 2, and follow up Months 2, 4, 6 were 6, and 33, 29, 29, respectively.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Week 2 of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.38" spread="512.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Month 2 Follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.46" spread="34.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Month 4 Follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.08" spread="35.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 Follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.70" spread="18.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population</title>
        <description>Anti-leptin antibodies measured at Weeks 1 and 2 of drug treatment, early termination visit, and at Months 2, 4, and 6 post treatment follow-up in participants who received metreleptin.</description>
        <time_frame>Week 1 to Month 6 Follow-Up</time_frame>
        <population>All participants who received at least one dose of metreleptin and provided a sample to analyze; number analyzed (n) for Week 1, Week 2, early termination, Month 2, Month 4, Month 6 Follow-up were: n=22, 5, 35, 32, 25, 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-leptin Antibodies Who Received Metreleptin - Intent to Treat Population</title>
          <description>Anti-leptin antibodies measured at Weeks 1 and 2 of drug treatment, early termination visit, and at Months 2, 4, and 6 post treatment follow-up in participants who received metreleptin.</description>
          <population>All participants who received at least one dose of metreleptin and provided a sample to analyze; number analyzed (n) for Week 1, Week 2, early termination, Month 2, Month 4, Month 6 Follow-up were: n=22, 5, 35, 32, 25, 28.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Neutralizing Activity to Metreleptin at Early Termination or During Post Treatment Follow-Up - Intent to Treat Population Who Received Metreleptin</title>
        <description>In vitro assays were conducted to determine if neutralizing activity to metreleptin developed in participants treated with at least one dose of the drug during the study. Baseline is Day 1 of the Randomization Period, prior to administration of metreleptin.</description>
        <time_frame>Baseline to Month 6 Follow-Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutralizing Activity to Metreleptin at Early Termination or During Post Treatment Follow-Up - Intent to Treat Population Who Received Metreleptin</title>
          <description>In vitro assays were conducted to determine if neutralizing activity to metreleptin developed in participants treated with at least one dose of the drug during the study. Baseline is Day 1 of the Randomization Period, prior to administration of metreleptin.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hematology and Urinalysis Laboratory Values of Potential Clinical Importance - Intent to Treat Population</title>
        <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Platelets high (H) &gt;500,000/µL; low (L) &lt;75,000/µL. Hematocrit males &lt;36%, females &lt;30%. Hemoglobin males &lt;12 g/dL, females &lt;10 g/dL. White blood cell count (WBC) H &gt;18,000/µL; L &lt;1,500/µL. Urine protein H &gt;= 3+ or &gt;= 500 mg/dL. Urine glucose H &gt;= 3+ or &gt;= 500 mg/dL. Urine ketones &gt;= 3+ or Large.</description>
        <time_frame>Screening to 6 Month Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. Number analyzed (n) in ITT included participants who provided a laboratory measurement. Hemoglobin, hematocrit n=27, 29 in placebo and pramlintide + metreleptin, respectively; urinalysis n=31, 29, in placebo and pramlintide + metreleptin, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology and Urinalysis Laboratory Values of Potential Clinical Importance - Intent to Treat Population</title>
          <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Platelets high (H) &gt;500,000/µL; low (L) &lt;75,000/µL. Hematocrit males &lt;36%, females &lt;30%. Hemoglobin males &lt;12 g/dL, females &lt;10 g/dL. White blood cell count (WBC) H &gt;18,000/µL; L &lt;1,500/µL. Urine protein H &gt;= 3+ or &gt;= 500 mg/dL. Urine glucose H &gt;= 3+ or &gt;= 500 mg/dL. Urine ketones &gt;= 3+ or Large.</description>
          <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. Number analyzed (n) in ITT included participants who provided a laboratory measurement. Hemoglobin, hematocrit n=27, 29 in placebo and pramlintide + metreleptin, respectively; urinalysis n=31, 29, in placebo and pramlintide + metreleptin, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose in Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Chemistry Laboratory Value of Potential Clinical Importance - Intent to Treat Population</title>
        <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Total bilirubin High (H) &gt; 2 mg/dL; Plasma or serum glucose fasting or non-fasting H &gt; 200 mg/dL, low (L) &lt; 60 mg/dL; Albumin L &lt;2.5 g/dL; Creatine kinase H &gt; 3*Upper limit of Normal (ULN); Sodium L &lt;130 milliequivalents per liter (mEq/L), H &gt; 150 mEq/L; potassium L&lt;3.0 mEq/L, H&gt; 5.5 mEq/L; bicarbonate L&lt;18 mEq/L, H&gt;35 mEq/L;calcium L &lt;8mg/dL, H&gt; 11 mg/dL; triglycerides H&gt; 500 mg/dL; Cholesterol L &lt; 100 mg/dL, H &gt; 350 mg/dL; Alkaline phosphatase H &gt; 3*ULN; Gamma-glutamyltransferase H&gt;3*ULN; creatinine males &gt; 1.6 mg/dL, females &gt; 1.4 mg/dL; alanine aminotransferase H &gt; 3*ULN; aspartate aminotransferase H &gt; 3*ULN; urea nitrogen H &gt; 45 mg/dL; uric acid males &gt; 10.0 mg/dL, females &gt; 8.0 mg/dL; Phosphorus L &lt; 1.0 mg/dL H &gt; 6.0 mg/dL.</description>
        <time_frame>Screening to Month 6 Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a laboratory measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chemistry Laboratory Value of Potential Clinical Importance - Intent to Treat Population</title>
          <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Total bilirubin High (H) &gt; 2 mg/dL; Plasma or serum glucose fasting or non-fasting H &gt; 200 mg/dL, low (L) &lt; 60 mg/dL; Albumin L &lt;2.5 g/dL; Creatine kinase H &gt; 3*Upper limit of Normal (ULN); Sodium L &lt;130 milliequivalents per liter (mEq/L), H &gt; 150 mEq/L; potassium L&lt;3.0 mEq/L, H&gt; 5.5 mEq/L; bicarbonate L&lt;18 mEq/L, H&gt;35 mEq/L;calcium L &lt;8mg/dL, H&gt; 11 mg/dL; triglycerides H&gt; 500 mg/dL; Cholesterol L &lt; 100 mg/dL, H &gt; 350 mg/dL; Alkaline phosphatase H &gt; 3*ULN; Gamma-glutamyltransferase H&gt;3*ULN; creatinine males &gt; 1.6 mg/dL, females &gt; 1.4 mg/dL; alanine aminotransferase H &gt; 3*ULN; aspartate aminotransferase H &gt; 3*ULN; urea nitrogen H &gt; 45 mg/dL; uric acid males &gt; 10.0 mg/dL, females &gt; 8.0 mg/dL; Phosphorus L &lt; 1.0 mg/dL H &gt; 6.0 mg/dL.</description>
          <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a laboratory measurement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatine Kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Month 6 Follow-Up in Blood Pressure - Intent to Treat Population</title>
        <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow-up was up to 6 months post treatment. Blood pressure included systolic and diastolic pressures measured in millimeters of mercury (mmHg).</description>
        <time_frame>Baseline to Month 6 Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of drug treatment. The number analyzed in the ITT included those participants who provided a vital sign measurement up to 6 Months follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Month 6 Follow-Up in Blood Pressure - Intent to Treat Population</title>
          <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow-up was up to 6 months post treatment. Blood pressure included systolic and diastolic pressures measured in millimeters of mercury (mmHg).</description>
          <population>The intent to treat (ITT) population received at least one dose of drug treatment. The number analyzed in the ITT included those participants who provided a vital sign measurement up to 6 Months follow-up.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="9.40"/>
                    <measurement group_id="O2" value="3.1" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="7.40"/>
                    <measurement group_id="O2" value="2.7" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Month 6 Follow-Up in Heart Rate - Intent to Treat Population</title>
        <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Heart rate was measured in beats per minute (beats/min).</description>
        <time_frame>Baseline up to Month 6 Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a vital sign measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Month 6 Follow-Up in Heart Rate - Intent to Treat Population</title>
          <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Heart rate was measured in beats per minute (beats/min).</description>
          <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a vital sign measurement.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="8.85"/>
                    <measurement group_id="O2" value="1.2" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to 6 Month Follow-Up in Fasting Plasma Glucose - Intent to Treat Population</title>
        <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Fasting glucose measured in milligrams per deciliter (mg/dL).</description>
        <time_frame>Baseline to 6 Month Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a laboratory measurement up to Month 6 Follow-Up.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 6 Month Follow-Up in Fasting Plasma Glucose - Intent to Treat Population</title>
          <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Fasting glucose measured in milligrams per deciliter (mg/dL).</description>
          <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a laboratory measurement up to Month 6 Follow-Up.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="8.31"/>
                    <measurement group_id="O2" value="-1.0" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Month 6 Follow-Up in Insulin - Intent to Treat Population</title>
        <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Insulin measured in milliunits per liter (mU/L).</description>
        <time_frame>Baseline up to Month 6 Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a laboratory measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Month 6 Follow-Up in Insulin - Intent to Treat Population</title>
          <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Insulin measured in milliunits per liter (mU/L).</description>
          <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a laboratory measurement.</population>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="8.990"/>
                    <measurement group_id="O2" value="3.46" spread="7.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Month 6 Follow-Up in Lipids - Intent to Treat Population</title>
        <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Lipids measured included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and triglycerides. Lipids were measured in milligrams per deciliter (mg/dL).</description>
        <time_frame>Baseline up to Month 6 Follow-Up</time_frame>
        <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a laboratory measurement up to Month 6 Follow-Up.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered SC injection of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) BID for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide + Metreleptin</title>
            <description>Self administered SC injection of pramlintide 360 µg + metreleptin 5.0 mg BID for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Month 6 Follow-Up in Lipids - Intent to Treat Population</title>
          <description>Baseline was Day 1 measurement or the last measurement taken prior to first dose of randomized study medication, if Day 1 measure was missing. Follow up was 6 months post last dose of randomized study medication. Lipids measured included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and triglycerides. Lipids were measured in milligrams per deciliter (mg/dL).</description>
          <population>The intent to treat (ITT) population received at least one dose of randomized study treatment. The number analyzed in the ITT included those participants who provided a laboratory measurement up to Month 6 Follow-Up.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="19.21"/>
                    <measurement group_id="O2" value="14.7" spread="25.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="7.25"/>
                    <measurement group_id="O2" value="6.6" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="17.47"/>
                    <measurement group_id="O2" value="9.6" spread="21.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="35.12"/>
                    <measurement group_id="O2" value="3.0" spread="38.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events (AEs) and Serious AEs (SAEs): onset date/ time on or after first dose of randomized study medication and on or before the last dose of randomized study medication.</time_frame>
      <desc>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition. SAE=medical event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo-P + Placebo-M</title>
          <description>Self administered subcutaneous injection once a day (QD) of placebo matched to pramlintide (Placebo-P) plus placebo matched to metreleptin (Placebo-M) for 1 week followed by BID dosing for 15 weeks (16 weeks total).</description>
        </group>
        <group group_id="E2">
          <title>Pramlintide + Metreleptin</title>
          <description>Self administered subcutaneous injection once a day (QD) of pramlintide 360 micrograms (µg) plus metreleptin 5.0 milligrams (mg ) for 1 week followed by twice a week (BID) dosing for 15 weeks (Total of 16 Weeks treatment).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Ohman, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

